Merger Between Kyowa Hakko And Kirin Launches New Company
This article was originally published in PharmAsia News
Oct. 1 marks the official start for Kyowa Hakko Kirin, a new company created by the merger of Kyowa Hakko and Kirin Pharmaceutical. Aiming to achieve ¥513 billion in sales by 2010 and become a top class specialty pharmaceutical company in the world, the merged company plans to accelerate research and development activities and launch two antibody products and two low-molecular chemical compounds each year. The new president Yuzuru Matsuda commented that to achieve the goals, the company has to maximum its unique strength in antibody technology. On the same day, Kyowa Hakko spun off its biochemical business, which became Kyowa Hokko Bio. (Click here for more - Japanese language
You may also be interested in...
The efforts to upgrade FDA’s information technology infrastructure may be opening up into an opportunity to reinvent its processes for regulatory decision making.
FDA should have all coronavirus vaccines evaluated by Vaccines and Related Biological Products Advisory Committee before approval, Democratic senators and representatives say; House subcommittee also wants FDA to require 30,000 participants in Phase III trials.
Biocon’s itolizumab gets clearance in India for restricted emergency use in COVID-19 patients, amid some concerns around small study numbers. But company says data are compelling and cites compassionate use substantiation, while partner Equillium expects to pursue a global study under US IND.